Abigail J S Armstrong1,2, Michael Shaffer1,3, Nichole M Nusbacher1, Christine Griesmer4, Suzanne Fiorillo4, Jennifer M Schneider1, C Preston Neff1, Sam X Li1, Andrew P Fontenot1, Thomas Campbell4, Brent E Palmer5, Catherine A Lozupone6. 1. Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. 2. Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. 3. Computational Bioscience Program, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. 4. Department of Surgery, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. 5. Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. brent.palmer@ucdenver.edu. 6. Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. catherine.lozupone@ucdenver.edu.
Abstract
BACKGROUND: Gut microbiome characteristics associated with HIV infection are of intense research interest but a deep understanding has been challenged by confounding factors across studied populations. Notably, a Prevotella-rich microbiome described in HIV-infected populations is now understood to be common in men who have sex with men (MSM) regardless of HIV status, but driving factors and potential health implications are unknown. RESULTS: Here, we further define the MSM-associated gut microbiome and describe compositional differences between the fecal microbiomes of Prevotella-rich MSM and non-MSM that may underlie observed pro-inflammatory properties. Furthermore, we show relatively subtle gut microbiome changes in HIV infection in MSM and women that include an increase in potential pathogens that is ameliorated with antiretroviral therapy (ART). Lastly, using a longitudinal cohort, we describe microbiome changes that happen after ART initiation. CONCLUSIONS: This study provides an in-depth characterization of microbiome differences that occur in a US population infected with HIV and demonstrates the degree to which these differences may be driven by lifestyle factors, ART, and HIV infection itself. Understanding microbiome compositions that occur with sexual behaviors that are high risk for acquiring HIV and untreated and ART-treated HIV infection will guide the investigation of immune and metabolic functional implications to ultimately target the microbiome therapeutically.
BACKGROUND:Gut microbiome characteristics associated with HIV infection are of intense research interest but a deep understanding has been challenged by confounding factors across studied populations. Notably, a Prevotella-rich microbiome described in HIV-infected populations is now understood to be common in men who have sex with men (MSM) regardless of HIV status, but driving factors and potential health implications are unknown. RESULTS: Here, we further define the MSM-associated gut microbiome and describe compositional differences between the fecal microbiomes of Prevotella-rich MSM and non-MSM that may underlie observed pro-inflammatory properties. Furthermore, we show relatively subtle gut microbiome changes in HIV infection in MSM and women that include an increase in potential pathogens that is ameliorated with antiretroviral therapy (ART). Lastly, using a longitudinal cohort, we describe microbiome changes that happen after ART initiation. CONCLUSIONS: This study provides an in-depth characterization of microbiome differences that occur in a US population infected with HIV and demonstrates the degree to which these differences may be driven by lifestyle factors, ART, and HIV infection itself. Understanding microbiome compositions that occur with sexual behaviors that are high risk for acquiring HIV and untreated and ART-treated HIV infection will guide the investigation of immune and metabolic functional implications to ultimately target the microbiome therapeutically.
Entities:
Keywords:
Antiretroviral therapy (ART); Human immunodeficiency virus (HIV); Men who have sex with men (MSM); Microbiome
Authors: Piotr Nowak; Marius Troseid; Ekatarina Avershina; Babilonia Barqasho; Ujjwal Neogi; Kristian Holm; Johannes R Hov; Kajsa Noyan; Jan Vesterbacka; Jenny Svärd; Knut Rudi; Anders Sönnerborg Journal: AIDS Date: 2015-11-28 Impact factor: 4.177
Authors: T E Taha; D R Hoover; G A Dallabetta; N I Kumwenda; L A Mtimavalye; L P Yang; G N Liomba; R L Broadhead; J D Chiphangwi; P G Miotti Journal: AIDS Date: 1998-09-10 Impact factor: 4.177
Authors: Sara Gianella; Matthew C Strain; Steffney E Rought; Milenka V Vargas; Susan J Little; Douglas D Richman; Celsa A Spina; Davey M Smith Journal: J Virol Date: 2011-11-23 Impact factor: 5.103
Authors: Jan Vesterbacka; Javier Rivera; Kajsa Noyan; Mariona Parera; Ujjwal Neogi; Malu Calle; Roger Paredes; Anders Sönnerborg; Marc Noguera-Julian; Piotr Nowak Journal: Sci Rep Date: 2017-07-24 Impact factor: 4.379
Authors: C F Kelley; C S Kraft; T Jb de Man; C Duphare; H-W Lee; J Yang; K A Easley; G K Tharp; M J Mulligan; P S Sullivan; S E Bosinger; R R Amara Journal: Mucosal Immunol Date: 2016-11-16 Impact factor: 7.313
Authors: Luke R Thompson; Jon G Sanders; Daniel McDonald; Amnon Amir; Joshua Ladau; Kenneth J Locey; Robert J Prill; Anupriya Tripathi; Sean M Gibbons; Gail Ackermann; Jose A Navas-Molina; Stefan Janssen; Evguenia Kopylova; Yoshiki Vázquez-Baeza; Antonio González; James T Morton; Siavash Mirarab; Zhenjiang Zech Xu; Lingjing Jiang; Mohamed F Haroon; Jad Kanbar; Qiyun Zhu; Se Jin Song; Tomasz Kosciolek; Nicholas A Bokulich; Joshua Lefler; Colin J Brislawn; Gregory Humphrey; Sarah M Owens; Jarrad Hampton-Marcell; Donna Berg-Lyons; Valerie McKenzie; Noah Fierer; Jed A Fuhrman; Aaron Clauset; Rick L Stevens; Ashley Shade; Katherine S Pollard; Kelly D Goodwin; Janet K Jansson; Jack A Gilbert; Rob Knight Journal: Nature Date: 2017-11-01 Impact factor: 49.962
Authors: Robert A Koeth; Zeneng Wang; Bruce S Levison; Jennifer A Buffa; Elin Org; Brendan T Sheehy; Earl B Britt; Xiaoming Fu; Yuping Wu; Lin Li; Jonathan D Smith; Joseph A DiDonato; Jun Chen; Hongzhe Li; Gary D Wu; James D Lewis; Manya Warrier; J Mark Brown; Ronald M Krauss; W H Wilson Tang; Frederic D Bushman; Aldons J Lusis; Stanley L Hazen Journal: Nat Med Date: 2013-04-07 Impact factor: 53.440
Authors: Susan A Tuddenham; Wei Li A Koay; Ni Zhao; James R White; Khalil G Ghanem; Cynthia L Sears Journal: Clin Infect Dis Date: 2020-02-03 Impact factor: 9.079
Authors: Abigail J S Armstrong; Michael Shaffer; Nichole M Nusbacher; Christine Griesmer; Suzanne Fiorillo; Jennifer M Schneider; C Preston Neff; Sam X Li; Andrew P Fontenot; Thomas Campbell; Brent E Palmer; Catherine A Lozupone Journal: Microbiome Date: 2020-04-06 Impact factor: 14.650
Authors: Scott Sherrill-Mix; Kaleigh Connors; Grace M Aldrovandi; Jason M Brenchley; Charles Boucher; Frederic D Bushman; Ronald G Collman; Satya Dandekar; Nichole R Klatt; Laurel A Lagenaur; Roger Paredes; Gilda Tachedjian; Jim A Turpin; Alan L Landay; Mimi Ghosh Journal: AIDS Res Hum Retroviruses Date: 2020-09-07 Impact factor: 2.205
Authors: Scott Sherrill-Mix; Michelle Yang; Grace M Aldrovandi; Jason M Brenchley; Frederic D Bushman; Ronald G Collman; Satya Dandekar; Nichole R Klatt; Laurel A Lagenaur; Alan L Landay; Roger Paredes; Gilda Tachedjian; Jim A Turpin; Sergio Serrano-Villar; Catherine A Lozupone; Mimi Ghosh Journal: AIDS Res Hum Retroviruses Date: 2022-01-25 Impact factor: 2.205
Authors: Gregory J Grosicki; Bryan L Riemann; Andrew A Flatt; Taylor Valentino; Michael S Lustgarten Journal: Sleep Med Date: 2020-04-23 Impact factor: 3.492
Authors: Vincent J Maffei; Robert W Siggins; Meng Luo; Meghan M Brashear; Donald E Mercante; Christopher M Taylor; Patricia Molina; David A Welsh Journal: J Infect Dis Date: 2021-03-29 Impact factor: 5.226